Neurocrine Biosciences (NBIX) Return on Capital Employed (2011 - 2026)

Neurocrine Biosciences' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 20.04% for Q1 2026.

• Quarterly Return on Capital Employed rose 448.0% year-over-year to 20.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.04% (up 448.0% YoY) and the FY2025 annual result came in at 18.04%, down 112.0% from the prior year.
• Return on Capital Employed was 20.04% for Q1 2026 at Neurocrine Biosciences, up from 16.71% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 20.04% in Q1 2026 and bottomed at 3.69% in Q2 2022.
• A 5-year average of 12.98% and a median of 15.27% in 2025 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 508 bps — and 2024, when it surged 1091 bps.
• Neurocrine Biosciences' Return on Capital Employed stood at 14.49% in 2022, then dropped by 28 bps to 10.48% in 2023, then surged by 75 bps to 18.29% in 2024, then slipped by 9 bps to 16.71% in 2025, then gained by 20 bps to 20.04% in 2026.
• Business Quant data shows NBIX's Return on Capital Employed at 20.04% in Q1 2026, 16.71% in Q4 2025, and 16.0% in Q3 2025.